<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12242171
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     09
    </month>
    <day>
     20
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     10
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1468-5833
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       325
      </volume>
      <issue>
       7365
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Sep
       </month>
       <day>
        21
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    </articletitle>
    <pagination>
     <medlinepgn>
      619
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Systematic review of randomised trials that compared at least 12 weeks' celecoxib treatment with another non-steroidal anti-inflammatory drug (NSAID) or placebo and reported efficacy, tolerability, or safety. Trials identified from manufacturer and by searching electronic databases and evaluated according to predefined inclusion and quality criteria. Data combined through meta-analysis.
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      15 187 patients with osteoarthritis or rheumatoid arthritis.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Efficacy: Western Ontario and McMaster universities osteoarthritis index; American College of Rheumatology responder index and joint scores for rheumatoid arthritis. Tolerability: withdrawal rates for adverse effects. Gastrointestinal safety: incidence of ulcers, bleeds, perforations, and obstructions.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Nine randomised controlled trials were included. Celecoxib and NSAIDS were equally effective for all efficacy outcomes. Compared with those taking other NSAIDs, in patients taking celecoxib the rate of withdrawals due to adverse gastrointestinal events was 46% lower (95% confidence interval 29% to 58%; NNT 35 at three months), the incidence of ulcers detectable by endoscopy was 71% lower (59% to 79%; NNT 6 at three months), and the incidence of symptoms of ulcers, perforations, bleeds, and obstructions was 39% lower (4% to 61%; NNT 208 at six months). Subgroup analysis of patients taking aspirin showed that the incidence of ulcers detected by endoscopy was reduced by 51% (14% to 72%) in those given celecoxib compared with other NSAIDs. The reduction was greater (73%, 52% to 84%) in those not taking aspirin.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability.
     </abstracttext>
    </abstract>
    <affiliation>
     Centre for Statistics in Medicine, Institute of Health Sciences, Headington, Oxford OX3 7LF. jon.deeks@cancer.org.uk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Deeks
      </lastname>
      <forename>
       Jonathan J
      </forename>
      <initials>
       JJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Smith
      </lastname>
      <forename>
       Lesley A
      </forename>
      <initials>
       LA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bradley
      </lastname>
      <forename>
       Matthew D
      </forename>
      <initials>
       MD
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Inflammatory Agents, Non-Steroidal
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cyclooxygenase Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pyrazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Sulfonamides
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      169590-42-5
     </registrynumber>
     <nameofsubstance>
      celecoxib
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-78-2
     </registrynumber>
     <nameofsubstance>
      Aspirin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 2002 Jun 1;324(7349):1287-8
     </refsource>
     <pmid version="1">
      12039807
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 2001 Aug 11;323(7308):301
     </refsource>
     <pmid version="1">
      11498480
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1990 Feb 3;300(6720):278-84
     </refsource>
     <pmid version="1">
      2106956
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Aliment Pharmacol Ther. 1997 Apr;11(2):283-91
     </refsource>
     <pmid version="1">
      9146764
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Care Res. 2000 Apr;13(2):112-21
     </refsource>
     <pmid version="1">
      14635284
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Rheumatol. 2001 Jan;28(1):6-11
     </refsource>
     <pmid version="1">
      11196544
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
     </refsource>
     <pmid version="1">
      11087881
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 2000 Sep 13;284(10):1247-55
     </refsource>
     <pmid version="1">
      10979111
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Pharmacotherapy. 1999 Nov;19(11):1269-78
     </refsource>
     <pmid version="1">
      10555933
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Mayo Clin Proc. 1999 Nov;74(11):1095-105
     </refsource>
     <pmid version="1">
      10560596
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1999 Nov 24;282(20):1921-8
     </refsource>
     <pmid version="1">
      10580457
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1999 Dec 18-25;354(9196):2106-11
     </refsource>
     <pmid version="1">
      10609815
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Pain. 2000 Mar;85(1-2):169-82
     </refsource>
     <pmid version="1">
      10692616
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2002 Sep 21;325(7365):607-8
     </refsource>
     <pmid version="1">
      12242157
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Fam Pract. 2003 Feb;52(2):96-8
     </refsource>
     <pmid version="1">
      12585981
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2003 Feb 8;326(7384):334; author reply 334
     </refsource>
     <pmid version="1">
      12575714
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2003 Feb 8;326(7384):334; author reply 334
     </refsource>
     <pmid version="1">
      12574052
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Inflammatory Agents, Non-Steroidal
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Arthritis, Rheumatoid
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aspirin
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cyclooxygenase Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastrointestinal Diseases
     </descriptorname>
     <qualifiername majortopicyn="Y">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteoarthritis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyrazoles
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
     <qualifiername majortopicyn="N">
      methods
     </qualifiername>
     <qualifiername majortopicyn="N">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sulfonamides
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    13
   </numberofreferences>
   <otherid source="NLM">
    PMC126301
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      9
     </month>
     <day>
      21
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      10
     </month>
     <day>
      9
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      9
     </month>
     <day>
      21
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12242171
    </articleid>
    <articleid idtype="pmc">
     PMC126301
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

